If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

Biogen has filed their SOD1-lowering drug tofersen for accelerated approval for amyotrophic lateral sclerosis (ALS), even though the pivotal trial of the drug missed its primary efficacy endpoint.

The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

Biogen hasn’t let a phase 3 failure for tofersen ... for a new drug application of the amyotrophic lateral sclerosis (ALS) drug. If approved, the Ionis Pharmaceuticals-partnered prospect would ...

Tuesday, the FDA granted an accelerated approval to Biogen and Ionis’ tofersen to treat patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the SOD1 gene. The drug ...

according to the ALS Association. Soon after her diagnosis, Green learned about a clinical trial at Mass General for an experimental drug — QALSODY® (tofersen), which is made by Biogen in ...

Alzheimer’s disease, Parkinson’s disease and ALS are some of the toughest problems in medicine. Biogen Inc. wants to make drugs for all of them. It’s an ambitious goal that could produce med ...

Due to increased competitive pressure, sales of the Biogen drug have declined almost ... patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS). Qalsody was also approved ...

Biogen has stopped developing at least five neuroscience therapies since the beginning of the year. The slimming of the Cambridge company’s drug pipeline comes as the firm struggles to regain ...

Ionis licensed this drug to Biogen, which is responsible for ... which was approved by the FDA in April 2023 for amyotrophic ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.86, ...